Arterial hypertension in cancer: The elephant in the room.

[1]  G. Lip,et al.  2018 ESC/ESH Guidelines for the management of arterial hypertension. , 2018, European heart journal.

[2]  H. Goldschmidt,et al.  Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA) , 2018, Haematologica.

[3]  S. Russell,et al.  Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials. , 2018, Blood advances.

[4]  M. Metra,et al.  Mechanism of cardiovascular toxicity by proteasome inhibitors: New paradigm derived from clinical and pre-clinical evidence. , 2018, European journal of pharmacology.

[5]  A. Cohen-Solal,et al.  Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge , 2018, European journal of heart failure.

[6]  J. Moreb,et al.  Efficacy and safety of carfilzomib in relapsed and/or refractory multiple myeloma: systematic review and meta-analysis of 14 trials , 2018, Oncotarget.

[7]  M. Volpe,et al.  Inflammatory residual risk: An emerging target to reduce cardiovascular disease? , 2018, Clinical cardiology.

[8]  R. Touyz,et al.  VEGFR (Vascular Endothelial Growth Factor Receptor) Inhibition Induces Cardiovascular Damage via Redox-Sensitive Processes , 2018, Hypertension.

[9]  R. Touyz,et al.  Vascular toxicities with VEGF inhibitor therapies–focus on hypertension and arterial thrombotic events , 2018, Journal of the American Society of Hypertension : JASH.

[10]  Dae Hyun Lee,et al.  Cardiovascular Complications of Multiple Myeloma Treatment: Evaluation, Management, and Prevention , 2018, Current Treatment Options in Cardiovascular Medicine.

[11]  D. Harrison,et al.  Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor–Associated Hypertension and Vascular Disease , 2018, Hypertension.

[12]  A. Di Meglio,et al.  Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes , 2018, Therapeutic advances in medical oncology.

[13]  M. Volpe,et al.  Is early and fast blood pressure control important in hypertension management? , 2017, International journal of cardiology.

[14]  G. Tortora,et al.  The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer , 2017, Clinical genitourinary cancer.

[15]  Jonathon B. Cohen,et al.  PI3K Inhibitors: Understanding Toxicity Mechanisms and Management. , 2017, Oncology.

[16]  E. Yeh,et al.  Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1. , 2017, Journal of the American College of Cardiology.

[17]  A. de la Sierra,et al.  Personalised Single-Pill Combination Therapy in Hypertensive Patients: An Update of a Practical Treatment Platform , 2017, High Blood Pressure & Cardiovascular Prevention.

[18]  G. Lenz,et al.  Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  D. Kroetz,et al.  Bevacizumab‐induced hypertension: Clinical presentation and molecular understanding , 2017, Pharmacology & therapeutics.

[20]  R. Iliescu,et al.  Recent Advances in Hypertension and Cardiovascular Toxicities With Vascular Endothelial Growth Factor Inhibition , 2017, Hypertension.

[21]  N. Sarrafzadegan,et al.  Cardiovascular disease and cancer: Evidence for shared disease pathways and pharmacologic prevention. , 2017, Atherosclerosis.

[22]  E. Zabor,et al.  Hypertension and VEGF (Vascular Endothelial Growth Factor) Receptor Tyrosine Kinase Inhibition: Effects on Renal Function , 2017, Hypertension.

[23]  P. Zinzani,et al.  Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  M. Volpe,et al.  Monotherapy and Dual Combination Therapies Based on Olmesartan: A Comprehensive Strategy to Improve Blood Pressure Control , 2017, High Blood Pressure & Cardiovascular Prevention.

[25]  T. Poussa,et al.  Angiotensin Inhibitors as Treatment of Sunitinib/Pazopanib‐induced Hypertension in Metastatic Renal Cell Carcinoma , 2017, Clinical genitourinary cancer.

[26]  R. Mrowka.  Arterial hypertension , 2017, Acta physiologica.

[27]  M. Baccarani,et al.  Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion , 2017, Annals of Hematology.

[28]  W. Guo,et al.  Hypertension and breast cancer risk: a systematic review and meta-analysis , 2017, Scientific Reports.

[29]  M. Fradley,et al.  Cardiovascular Complications of Targeted Therapies for Chronic Myeloid Leukemia , 2017, Current Treatment Options in Cardiovascular Medicine.

[30]  S. Antoniou,et al.  Current Situation of Medication Adherence in Hypertension , 2017, Front. Pharmacol..

[31]  D. Grimm,et al.  The Adverse Effect of Hypertension in the Treatment of Thyroid Cancer with Multi-Kinase Inhibitors , 2017, International journal of molecular sciences.

[32]  Douglas S. Lee,et al.  Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis. , 2017, Cancer treatment reviews.

[33]  A. Russo,et al.  Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond. , 2017, International journal of cardiology.

[34]  F. Barlesi,et al.  Management and research in cancer treatment-related cardiovascular toxicity: Challenges and perspectives. , 2016, International journal of cardiology.

[35]  G. Lip,et al.  2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). , 2016, European heart journal.

[36]  Yuanyuan Zhang,et al.  Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients , 2016, Oncotarget.

[37]  R. Touyz,et al.  Vascular Complications of Cancer Chemotherapy , 2016, The Canadian journal of cardiology.

[38]  J. Sheeder,et al.  Bevacizumab induced hypertension in gynecologic cancer: Does it resolve after completion of therapy?☆ , 2016, Gynecologic oncology reports.

[39]  D. Mele,et al.  A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology , 2016, Journal of cardiovascular medicine.

[40]  J. Mikhael.  Management of Carfilzomib-Associated Cardiac Adverse Events. , 2016, Clinical lymphoma, myeloma & leukemia.

[41]  H. Gervásio,et al.  Association between bevacizumab-related hypertension and response to treatment in patients with metastatic colorectal cancer , 2016, ESMO Open.

[42]  S. Nomura,et al.  Retrospective analysis of bevacizumab‐induced hypertension and clinical outcome in patients with colorectal cancer and lung cancer , 2016, Cancer medicine.

[43]  A. Blaes,et al.  Shared Risk Factors in Cardiovascular Disease and Cancer , 2016, Circulation.

[44]  M. Fradley,et al.  Anti-VEGF-Induced Hypertension: a Review of Pathophysiology and Treatment Options , 2016, Current Treatment Options in Cardiovascular Medicine.

[45]  C. Torp‐Pedersen,et al.  Aalborg Universitet Associations between metabolic disorders and risk of cancer in Danish men and women a nationwide cohort study , 2016 .

[46]  S. Anai,et al.  The best objective response of target lesions and the incidence of treatment-related hypertension are associated with the survival of patients with metastatic renal cell carcinoma treated with sunitinib: a Japanese retrospective study , 2016, BMC Research Notes.

[47]  A. Dobson,et al.  Hypertension, antihypertensive treatment and cancer incidence and mortality: a pooled collaborative analysis of 12 Australian and New Zealand cohorts , 2016, Journal of hypertension.

[48]  A. Dobson,et al.  The metabolic syndrome and cancer: Is the metabolic syndrome useful for predicting cancer risk above and beyond its individual components? , 2015, Diabetes & metabolism.

[49]  Mellar P. Davis,et al.  Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients , 2015, British Journal of Cancer.

[50]  J. Moslehi,et al.  Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  M. Volpe,et al.  Reducing Cardiovascular and Cancer Risk: How to Address Global Primary Prevention in Clinical Practice , 2015, Clinical cardiology.

[52]  G. Le Teuff,et al.  Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma. , 2015 .

[53]  L. Jeng,et al.  Hypertension and Subsequent Genitourinary and Gynecologic Cancers Risk , 2015, Medicine.

[54]  W. Martins,et al.  Hypertension in Patients with Cancer , 2015, Arquivos brasileiros de cardiologia.

[55]  R. Soares,et al.  Metabolic syndrome and risk of cancer: which link? , 2015, Metabolism: clinical and experimental.

[56]  C. García-Girón,et al.  Correlation of Hypertension and Proteinuria with Outcome in Elderly Bevacizumab-Treated Patients with Metastatic Colorectal Cancer , 2015, PloS one.

[57]  T. Choueiri,et al.  Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway , 2015, Cancer.

[58]  A. Torbicki,et al.  Pre-existing arterial hypertension as a risk factor for early left ventricular systolic dysfunction following (R)-CHOP chemotherapy in patients with lymphoma. , 2014, Journal of the American Society of Hypertension : JASH.

[59]  R. Touyz,et al.  Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome. , 2014, The Canadian journal of cardiology.

[60]  L. Kuller,et al.  Hypertension and Obesity and the Risk of Kidney Cancer in 2 Large Cohorts of US Men and Women , 2014, Hypertension.

[61]  B. Ky,et al.  Cancer Therapy–Induced Cardiotoxicity: Basic Mechanisms and Potential Cardioprotective Therapies , 2014, Journal of the American Heart Association.

[62]  S. Landis,et al.  Incidence of New-Onset Hypertension in Cancer Patients: A Retrospective Cohort Study , 2013, International journal of hypertension.

[63]  C. Autore,et al.  Arterial thrombotic events and acute coronary syndromes with cancer drugs: are growth factors the missed link?: what both cardiologist and oncologist should know about novel angiogenesis inhibitors. , 2013, International journal of cardiology.

[64]  Y. Lam,et al.  Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study. , 2013, International journal of cardiology.

[65]  C. Coppola,et al.  The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors , 2013, European journal of heart failure.

[66]  Paolo Chiodini,et al.  Metabolic Syndrome and Risk of Cancer , 2012, Diabetes Care.

[67]  J. Moslehi,et al.  Management of antiangiogenic therapy-induced hypertension. , 2012, Hypertension.

[68]  P. Stattin,et al.  Blood Pressure and Risk of Cancer Incidence and Mortality in the Metabolic Syndrome and Cancer Project , 2012, Hypertension.

[69]  C. Hughes,et al.  Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review , 2012, Cancer Causes & Control.

[70]  J. Rosenberg,et al.  Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer , 2012, Drug design, development and therapy.

[71]  C. la Vecchia,et al.  The metabolic syndrome and risk of prostate cancer in Italy. , 2011, Annals of epidemiology.

[72]  M. Dimopoulos,et al.  The use of 24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renal cancer. , 2011, European journal of cancer.

[73]  G. Mantovani,et al.  Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. , 2010, American heart journal.

[74]  M. Maitland,et al.  Ambulatory Monitoring Detects Sorafenib-Induced Blood Pressure Elevations on the First Day of Treatment , 2009, Clinical Cancer Research.

[75]  J. Soria,et al.  Review Management of Hypertension in Angiogenesis Inhibitor-treated Patients , 2022 .

[76]  W. Tsai,et al.  Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  J. Goodwin,et al.  Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  A. Dogan,et al.  Protective effects of carvedilol against anthracycline-induced cardiomyopathy. , 2006, Journal of the American College of Cardiology.

[79]  S. Fosså,et al.  Components of the metabolic syndrome in long-term survivors of testicular cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[80]  J. Baars,et al.  Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. , 2006, Blood.

[81]  K. Ohta,et al.  Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone , 2005, Cancer.

[82]  T. Wilsgaard,et al.  Blood pressure and body mass index in long-term survivors of testicular cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  J. Tuomilehto,et al.  Cancer pattern among hypertensive patients in North Karelia, Finland , 2005, Journal of Human Hypertension.

[84]  A. Ballestrero,et al.  Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. , 2004, Journal of molecular and cellular cardiology.

[85]  Edward L Spitznagel,et al.  Prognostic importance of comorbidity in a hospital-based cancer registry. , 2004, JAMA.

[86]  A. Moreno,et al.  Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy. , 2002, Toxicology and applied pharmacology.

[87]  D J van Veldhuisen,et al.  Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  Jeremiah Stamler,et al.  HIGH BLOOD-PRESSURE: A RISK FACTOR FOR CANCER MORTALITY ? , 1975, The Lancet.

[89]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[90]  P. Spallarossa,et al.  What the Oncologist Needs to Know: How to Ask for a Cardiology Consultation , 2017 .

[91]  D. Mele,et al.  A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology. , 2016, Journal of cardiovascular medicine.

[92]  L. Ruilope,et al.  Twisting arms to angiotensin receptor blockers/antagonists: the turn of cancer. , 2011, European heart journal.